Physician profile
Adrian Padkowsky
NPI 1447559943
$2,773.28
in general payments reported to CMS, 2019-2025
29 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $216 · 2021: $382 · 2022: $379 · 2023: $578 · 2024: $405 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $689.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $370.48 | 2020-2025 | Farxiga |
| Novo Nordisk INC | $366.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $293.70 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $232.24 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.22 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $78.36 | 2021-2025 | Hetlioz, Fanapt |
| Allergan, INC. | $66.42 | 2020 | |
| Horizon Therapeutics Plc | $58.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $55.59 | 2022-2025 | Zoryve |
| Biotronik Nro, INC. | $49.03 | 2025 | Prospera |
| Eisai INC. | $42.46 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $39.95 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $28.65 | 2024 | Rexulti |
| Mylan Specialty L.P. | $28.20 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $26.96 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.88 | 2021 | |
| Bausch Health US, LLC | $26.59 | 2021 | |
| Incyte Corporation | $21.49 | 2025 | Opzelura |
| Janssen Pharmaceuticals, INC | $21.36 | 2025 | Spravato |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.29 | 2024 | Quviviq |
| Genentech USA, INC. | $15.00 | 2019 | |
| Endo Pharmaceuticals INC. | $15.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.50 | 2022 | |
| Lilly USA, LLC | $12.69 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.24 | 2020 | |
| Aytu Biopharma, INC. | $11.50 | 2019 | |
| Merck Sharp & Dohme LLC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Padkowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.